drugset
drugset / Trial / NCT07253675

Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the Congo

NCT07253675 ↗

Phase 2 Not yet recruiting 180 enrolled Shanghai Institute Of Biological Products
RandomizedParallel-groupTriple-blindPrevention

Summary

To evaluate the safety and immunogenicity of the MVA-SIBP vaccine using a double-blind, randomized, controlled, age de-escalation design conducted in Kinshasa, Democratic Republic of the Congo (DRC).

Timeline

Start
2025-12-31
Primary completion
2027-02-28
Completion
2027-02-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator IMVAMUNE Vaccine 0.5 ml Subcutaneous
Subject MVA-SIBP Vaccine 0.5 ml Subcutaneous

Indications

monkeypox